Pascal Deschatelets - 21 Jan 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Reporting relationship: Chief Scientific Officer
Issuer ticker: APLS
Reported as of: 21 Jan 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 25 Jan 2022, 15:56:33 UTC
Prior SEC filing: 25 Jun 2021
Next SEC filing: 01 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ David Watson, attorney-in-fact for Pascal Deschatelets

Key filing fact

Pascal Deschatelets filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 25 Jan 2022.

Key facts

This page summarizes Pascal Deschatelets's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 25 Jan 2022, 15:56.

Change

Previous filing in this sequence was filed on 25 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

APLS transaction

Common Stock

Award

Transaction value: $0
Shares: +26,051
Change %: +3%
Price: $0.000000
Shares after: 895,638
Date: 21 Jan 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

APLS transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +36,951
Change %
Price: $0.000000
Shares after: 36,951
Date: 21 Jan 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 36,951
Exercise price: $35.46
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This represents a restricted stock unit grant made on January 21, 2022 that vests 25% annually in equal installments over four years from the date of grant, subject to continued service.

Footnote F2

This represents a non-qualified stock option grant made on January 21, 2022 that vests over a four year period with 25% vesting one year from grant date and the remaining 75% vesting in equal monthly installments thereafter through the fourth anniversary of the grant date, subject to continued service.